| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Expected but not Quantified |
|---|
| Creation Date | 2012-09-06 15:16:50 UTC |
|---|
| Update Date | 2022-03-07 02:51:45 UTC |
|---|
| HMDB ID | HMDB0014816 |
|---|
| Secondary Accession Numbers | |
|---|
| Metabolite Identification |
|---|
| Common Name | Losartan |
|---|
| Description | Losartan is an angiotensin-receptor blocker (ARB) that may be used alone or with other agents to treat hypertension. Losartan and its longer acting metabolite, E-3174, lower blood pressure by antagonizing the renin-angiotensin-aldosterone system (RAAS); they compete with angiotensin II for binding to the type-1 angiotensin II receptor (AT1) subtype and prevents the blood pressure increasing effects of angiotensin II. Unlike angiotensin-converting enzyme (ACE) inhibitors, ARBs do not have the adverse effect of dry cough. Losartan may be used to treat hypertension, isolated systolic hypertension, left ventricular hypertrophy and diabetic nephropathy. It may also be used as an alternative agent for the treatment of systolic dysfunction, myocardial infarction, coronary artery disease, and heart failure. |
|---|
| Structure | CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1 InChI=1S/C22H23ClN6O/c1-2-3-8-20-24-21(23)19(14-30)29(20)13-15-9-11-16(12-10-15)17-6-4-5-7-18(17)22-25-27-28-26-22/h4-7,9-12,30H,2-3,8,13-14H2,1H3,(H,25,26,27,28) |
|---|
| Synonyms | | Value | Source |
|---|
| (2-Butyl-4-chloro-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-imidazol-5-yl)methanol | ChEBI | | 2-N-Butyl-4-chloro-5-hydroxymethyl-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole | ChEBI | | Losartic | Kegg | | DUP 89 | HMDB | | Losartan potassium | HMDB | | DuP 753 | HMDB | | Potassium, losartan | HMDB | | 2-Butyl-4-chloro-1-((2'-(1H-etrazol-5-yl) (1,1'-biphenyl)-4-yl)methyl)-1H-imidazole-5-methanol | HMDB | | DuP-753 | HMDB | | Cozaar | HMDB | | Losartan monopotassium salt | HMDB | | Monopotassium salt, losartan | HMDB | | Salt, losartan monopotassium | HMDB |
|
|---|
| Chemical Formula | C22H23ClN6O |
|---|
| Average Molecular Weight | 422.911 |
|---|
| Monoisotopic Molecular Weight | 422.162187095 |
|---|
| IUPAC Name | [2-butyl-4-chloro-1-({4-[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)-1H-imidazol-5-yl]methanol |
|---|
| Traditional Name | losartan |
|---|
| CAS Registry Number | 114798-26-4 |
|---|
| SMILES | CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1 |
|---|
| InChI Identifier | InChI=1S/C22H23ClN6O/c1-2-3-8-20-24-21(23)19(14-30)29(20)13-15-9-11-16(12-10-15)17-6-4-5-7-18(17)22-25-27-28-26-22/h4-7,9-12,30H,2-3,8,13-14H2,1H3,(H,25,26,27,28) |
|---|
| InChI Key | PSIFNNKUMBGKDQ-UHFFFAOYSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as biphenyls and derivatives. These are organic compounds containing to benzene rings linked together by a C-C bond. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Benzenoids |
|---|
| Class | Benzene and substituted derivatives |
|---|
| Sub Class | Biphenyls and derivatives |
|---|
| Direct Parent | Biphenyls and derivatives |
|---|
| Alternative Parents | |
|---|
| Substituents | - Biphenyl
- Phenyltetrazole
- 1,2,4,5-tetrasubstituted imidazole
- Aryl chloride
- Aryl halide
- N-substituted imidazole
- Azole
- Heteroaromatic compound
- Imidazole
- Tetrazole
- Azacycle
- Organoheterocyclic compound
- Organonitrogen compound
- Organochloride
- Organohalogen compound
- Aromatic alcohol
- Alcohol
- Organic nitrogen compound
- Hydrocarbon derivative
- Organopnictogen compound
- Organic oxygen compound
- Organooxygen compound
- Primary alcohol
- Aromatic heteromonocyclic compound
|
|---|
| Molecular Framework | Aromatic heteromonocyclic compounds |
|---|
| External Descriptors | |
|---|
| Ontology |
|---|
| Physiological effect | Not Available |
|---|
| Disposition | |
|---|
| Process | |
|---|
| Role | Not Available |
|---|
| Physical Properties |
|---|
| State | Solid |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | 183.5 - 184.5 °C | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | 0.0047 g/L | Not Available | | LogP | 6.1 | Not Available |
|
|---|
| Experimental Chromatographic Properties | Experimental Collision Cross Sections |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 7.56 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 16.5923 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 1.28 minutes | 32390414 | | AjsUoB = Accucore 150 Amide HILIC with 10mM Ammonium Formate, 0.1% Formic Acid | 41.4 seconds | 40023050 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 2738.1 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 385.2 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 224.9 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 214.4 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 348.7 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 631.6 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 619.1 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 99.4 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 1514.1 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 595.6 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 1675.8 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 442.2 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 433.8 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 272.5 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 185.3 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 21.9 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| Losartan,1TMS,isomer #1 | CCCCC1=NC(Cl)=C(CO[Si](C)(C)C)N1CC1=CC=C(C2=CC=CC=C2C2=N[NH]N=N2)C=C1 | 3623.1 | Semi standard non polar | 33892256 | | Losartan,1TMS,isomer #2 | CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C2=CC=CC=C2C2=NN([Si](C)(C)C)N=N2)C=C1 | 3781.5 | Semi standard non polar | 33892256 | | Losartan,2TMS,isomer #1 | CCCCC1=NC(Cl)=C(CO[Si](C)(C)C)N1CC1=CC=C(C2=CC=CC=C2C2=NN([Si](C)(C)C)N=N2)C=C1 | 3785.9 | Semi standard non polar | 33892256 | | Losartan,2TMS,isomer #1 | CCCCC1=NC(Cl)=C(CO[Si](C)(C)C)N1CC1=CC=C(C2=CC=CC=C2C2=NN([Si](C)(C)C)N=N2)C=C1 | 3723.0 | Standard non polar | 33892256 | | Losartan,2TMS,isomer #1 | CCCCC1=NC(Cl)=C(CO[Si](C)(C)C)N1CC1=CC=C(C2=CC=CC=C2C2=NN([Si](C)(C)C)N=N2)C=C1 | 4606.0 | Standard polar | 33892256 | | Losartan,1TBDMS,isomer #1 | CCCCC1=NC(Cl)=C(CO[Si](C)(C)C(C)(C)C)N1CC1=CC=C(C2=CC=CC=C2C2=N[NH]N=N2)C=C1 | 3792.0 | Semi standard non polar | 33892256 | | Losartan,1TBDMS,isomer #2 | CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C2=CC=CC=C2C2=NN([Si](C)(C)C(C)(C)C)N=N2)C=C1 | 3906.6 | Semi standard non polar | 33892256 | | Losartan,2TBDMS,isomer #1 | CCCCC1=NC(Cl)=C(CO[Si](C)(C)C(C)(C)C)N1CC1=CC=C(C2=CC=CC=C2C2=NN([Si](C)(C)C(C)(C)C)N=N2)C=C1 | 4050.6 | Semi standard non polar | 33892256 | | Losartan,2TBDMS,isomer #1 | CCCCC1=NC(Cl)=C(CO[Si](C)(C)C(C)(C)C)N1CC1=CC=C(C2=CC=CC=C2C2=NN([Si](C)(C)C(C)(C)C)N=N2)C=C1 | 4171.2 | Standard non polar | 33892256 | | Losartan,2TBDMS,isomer #1 | CCCCC1=NC(Cl)=C(CO[Si](C)(C)C(C)(C)C)N1CC1=CC=C(C2=CC=CC=C2C2=NN([Si](C)(C)C(C)(C)C)N=N2)C=C1 | 4609.5 | Standard polar | 33892256 |
|
|---|
| GC-MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted GC-MS | Predicted GC-MS Spectrum - Losartan GC-MS (Non-derivatized) - 70eV, Positive | splash10-002r-4089100000-3b72c4e0ebc46e6402a9 | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Losartan GC-MS (1 TMS) - 70eV, Positive | splash10-00di-9002300000-8cb18ee6a14e321f81eb | 2017-10-06 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Losartan GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Experimental LC-MS/MS | LC-MS/MS Spectrum - Losartan LC-ESI-QFT , negative-QTOF | splash10-00di-0000900000-657db16bb4bfe9184114 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Losartan LC-ESI-QFT , negative-QTOF | splash10-056r-0900000000-43bb8508cd1dbc71bcee | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Losartan LC-ESI-QFT , negative-QTOF | splash10-004i-0900000000-55368087829d113fdb7b | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Losartan LC-ESI-QFT , negative-QTOF | splash10-004i-0900000000-af470646c547613f82a0 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Losartan LC-ESI-QFT , negative-QTOF | splash10-004i-0900000000-746dcf7a43a3f8839c1d | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Losartan LC-ESI-QFT , negative-QTOF | splash10-004i-0900000000-0bee80f7ccbc4b68eee0 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Losartan LC-ESI-QFT , negative-QTOF | splash10-004i-0900000000-d845ae166a10faff242a | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Losartan LC-ESI-QFT , negative-QTOF | splash10-004i-2900000000-d39a309c02e1aaa956b0 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Losartan LC-ESI-QFT , negative-QTOF | splash10-004i-7900000000-d27d10ab008deb157e7a | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Losartan LC-ESI-QFT , negative-QTOF | splash10-00fr-0900700000-fef78a7f52d4aa515bb4 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Losartan LC-ESI-QFT , negative-QTOF | splash10-00fr-0900600000-c62f0db44e17f79e0c70 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Losartan LC-ESI-QFT , positive-QTOF | splash10-0a4i-0034900000-22ba49ec64d374c8965e | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Losartan LC-ESI-QFT , positive-QTOF | splash10-0a4i-0191000000-8ff1b5a21f6ef4a462cd | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Losartan LC-ESI-QFT , positive-QTOF | splash10-0a4i-0590000000-9841ff7f881c3e9c11b9 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Losartan LC-ESI-QFT , positive-QTOF | splash10-0a59-0960000000-a24e287a018dae01dd0d | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Losartan LC-ESI-QFT , positive-QTOF | splash10-0a5c-0930000000-ff3e675bd445225bf04e | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Losartan LC-ESI-QFT , positive-QTOF | splash10-0pxu-0920000000-9adf4aef59fc1545fea6 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Losartan LC-ESI-QFT , positive-QTOF | splash10-0v00-1900000000-3591888cf5831cbe3d11 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Losartan LC-ESI-QFT , positive-QTOF | splash10-0wmi-2900000000-ab9304c8cebc201d0178 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Losartan 10V, Positive-QTOF | splash10-05fr-0021900000-2c231055acd0a8f296d3 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Losartan 20V, Positive-QTOF | splash10-052r-0195400000-b093eaecc05008eba3de | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Losartan 40V, Positive-QTOF | splash10-01p9-8392000000-dc1eae529c5259d2591b | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Losartan 10V, Negative-QTOF | splash10-00di-0304900000-071c5333315e558faa09 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Losartan 20V, Negative-QTOF | splash10-0a73-0709200000-be33ec2e3b5adaf0fb63 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Losartan 40V, Negative-QTOF | splash10-0v03-2900000000-2cc4dbb7931105738ba5 | 2016-08-03 | Wishart Lab | View Spectrum |
|
|---|
| General References | - Sica DA, Gehr TW, Ghosh S: Clinical pharmacokinetics of losartan. Clin Pharmacokinet. 2005;44(8):797-814. [PubMed:16029066 ]
- Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002 Mar 23;359(9311):995-1003. [PubMed:11937178 ]
- Guo ZX, Qiu MC: [Losartan downregulates the expression of transforming growth factor beta type I and type II receptors in kidney of diabetic rat]. Zhonghua Nei Ke Za Zhi. 2003 Jun;42(6):403-8. [PubMed:12895325 ]
- Habashi JP, Judge DP, Holm TM, Cohn RD, Loeys BL, Cooper TK, Myers L, Klein EC, Liu G, Calvi C, Podowski M, Neptune ER, Halushka MK, Bedja D, Gabrielson K, Rifkin DB, Carta L, Ramirez F, Huso DL, Dietz HC: Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science. 2006 Apr 7;312(5770):117-21. [PubMed:16601194 ]
- (). Bader, M. (2004). Renin-angiotensin-aldosterone system. In S. Offermanns, & W. Rosenthal (Eds.). Encyclopedic reference of molecular pharmacology_ (pp. 810-814). Berlin, Germany: Springer. . .
- (). FDA label . .
- (). Stanfield, C.L., & Germann, W.J. (2008). Principles of human physiology (3rd ed.). San Francisco, CA: Pearson Education, Inc.. .
|
|---|